New Trial for sGC Stimulator Treatment for Sickle Cell Disease

Sickle cell disease causes red blood cells to form abnormally, which disrupts oxygen function. Cancer Prevention Pharmaceuticals have been working with Vanderbilt Medical Center and NCI to start a new Phase II trial for a treatment. Researchers are measuring the effects of taking soluble guanylate cyclase (sGC) stimulator once a day by mouth.

Read the full article bioportfolio.com.


Follow us